Semaglutide is marketed as Wegovy for weight loss and Ozempic for diabetes
Most available information comes from clinical trials that focus on the individual safety profiles of each drug
Those who are considering weight loss medication may also be concerned about rare but serious long-term risks, which can include: Cardiovascular concerns (Increased heart attack risk in certain populations) Gallbladder disease Pancreatitis Other limitations include: Cost: Up to $1,000-1,200/month if not covered by insurance Supply shortages: Ongoing demand has outpaced availability Needle administration: Daily or weekly subcutaneous injections may deter some users For those with health conditions like heart disease, a history of pancreatitis, or certain genetic risks, these drugs may not be appropriate
Yes, injectable Retatrutide provides more consistent blood levels than oral alternatives because it bypasses the digestive system entirely
My blood sugar levels were in the controlled diabetic range, but I was having to take way more insulin than the average diabetic, injecting it in the abdomen no less than four times a day
Tirzepatide and semaglutide both support weight management, but they work differently